Testing of asymptomatic individuals during a routine general examination without abnormal findings for babesiosis, chikungunya virus, Colorado tick fever (CTF), dengue virus (DENV), ehrlichiosis/anaplasmosis, malaria, rickettsial disease, tickborne relapsing fever (TBRF), West Nile virus (WNV), yellow fever virus (YFV), or Zika virus DOES NOT MEET COVERAGE CRITERIA. This exclusion applies to screening in the absence of clinical signs, symptoms, or epidemiologic exposure sufficient to justify targeted diagnostic testing.

For Zika specifically, NAAT and/or IgM testing for non-pregnant individuals who have not traveled outside the United States and its territories and who are symptomatic for Zika virus infection does NOT meet coverage criteria; conversely, Zika NAAT/IgM with confirmatory PRNT meets coverage in the pregnancy- and exposure-specific scenarios described elsewhere in the policy.

Culture-based diagnostics are generally impractical for many vector-borne pathogens because several are obligate intracellular organisms requiring specialized cell culture techniques, extended incubation times, and high-biosafety facilities. As a result, culture is most often reserved for research or epidemiologic investigations rather than routine clinical diagnosis.

When culture is performed it should be limited to settings equipped for specialized microbiology and public health reference testing; routine clinical coverage does not extend to culture as a first-line diagnostic for pathogens for which more rapid, sensitive methods (NAAT, microscopy, serology) are available.

Routine hospital blood cultures cannot detect obligate intracellular rickettsial organisms and therefore are not a reliable diagnostic method for rickettsial diseases. Diagnosis relies on serologic testing (paired IFA IgG) and, when indicated, molecular testing or tissue-based methods (PCR or immunohistochemistry) performed at reference laboratories.

Because PCR of whole blood for Rickettsia rickettsii has low sensitivity in many cases (sensitivity increases in severe disease) and IFA is insensitive during the first week of illness, appropriate specimen selection and timing (acute and convalescent sera, or tissue when available) are important for accurate diagnosis.

IgG serologic assays (including IgG EIA and hemagglutination tests) are not recommended for diagnosis of acute dengue because they can reflect prior flavivirus infection or vaccination and may remain elevated indefinitely. For acute dengue diagnosis, rely on the recommended acute-phase testing combinations (NAAT/RT-PCR plus IgM, or NS1 ELISA plus IgM) within the first 0–7 days after symptom onset; use IgG only in paired sera demonstrating a fourfold rise when confirming recent infection.

In regions with co-circulating flaviviruses, positive serologic results should be interpreted cautiously and, when necessary, confirmed by plaque reduction neutralization test (PRNT) at reference laboratories due to cross-reactivity among flaviviruses.

Laboratory-developed tests (LDTs) are not FDA-approved but are regulated under CLIA as high-complexity tests. FDA clearance or approval is not required for clinical use of LDTs, but laboratories must validate and perform these assays in compliance with CLIA requirements.

The policy specifies covered diagnostic testing for a broad set of arthropod‑borne infections. Covered modalities include: for Babesiosis—Giemsa- or Wright-stained blood smear, NAAT on whole blood, and IgG or IgM IFA with initial and confirmatory testing spaced a minimum of two weeks apart; for Relapsing fevers—microscopy (dark-field or stained blood smears), NAAT for Borrelia spp. or B. miyamotoi, and serology as indicated (culture for Borrelia does NOT meet coverage); for Chikungunya and Colorado tick fever (CTF)—NAAT or viral culture during the acute viremic period and serology (IFA IgM) in later phases; for Dengue—NAAT/NS1 antigen plus IgM in the acute phase (0–7 days) and IgM ELISA as primary testing after day 7, with PRNT available for confirmatory testing; for Zika—NAAT and IgM testing meet coverage for pregnancy- and exposure-defined situations (NAAT up to 12 weeks in specified pregnant or exposure contexts and NAAT within 7 days for symptomatic recent travelers), with PRNT confirmatory testing when needed; for Ehrlichiosis/Anaplasmosis—NAAT on whole blood, IFA IgG, or microscopy for morulae meet coverage, whereas IFA IgM and standard blood culture do not; for Malaria—rapid diagnostic tests or smear microscopy (repeat every 12–24 hours up to 3 exams before ruling out) meet coverage and NAAT is appropriate to confirm Plasmodium species but IFA for Plasmodium antibodies does not meet coverage; for Rickettsial diseases—IFA IgG on paired acute and convalescent sera (minimum two weeks apart, demonstration of a fourfold rise is confirmatory) meets coverage, while whole‑blood NAAT and IFA IgM do not meet coverage in many contexts; for West Nile virus (WNV)—IgM serology (serum/CSF) and PRNT meet coverage, with NAAT meeting coverage only in immunocompromised individuals; and for Yellow fever virus (YFV)—early NAAT/virus isolation, IgM/IgG serology and confirmatory PRNT meet coverage and are reportable to public health authorities.

These coverage determinations align with cited guidance (CDC, IDSA/ASM, WHO) and emphasize specimen type and timing (acute vs convalescent), method-specific limitations (cross-reactivity of flavivirus serology, limited NAAT detection windows), and the role of reference labs for confirmatory testing such as PRNT.

As restated elsewhere in the policy, testing for the named vector-borne pathogens in asymptomatic individuals during a general exam without abnormal findings does not meet coverage criteria. This exclusion is explicit and applies across the listed infections unless other sections of the policy specify a covered indication tied to symptoms, exposure, pregnancy, or other clinical findings.

Providers should document symptoms, exposure history, travel, and specimen timing to support medical necessity when ordering covered testing and to avoid denial for screening without findings.

Rapid antigen tests such as the FDA‑approved BinaxNOW malaria RDT provide faster turnaround but have lower sensitivity in some settings (reported sensitivity ~84.2%) and can misclassify species, particularly in non-endemic areas. RDTs should be followed by microscopy for species confirmation and parasitemia quantification; reliance on RDTs alone in non-endemic settings is controversial and may lead to false positives or negatives.

Similarly, some rapid serologic assays for flaviviruses have specificity limitations; positive screening tests often require confirmation (e.g., PRNT) to resolve cross-reactivity with other flaviviruses.

PCR/NAAT has a limited role for initial, time-sensitive diagnosis of malaria in standard healthcare settings because turnaround times are typically longer than microscopy and RDTs. PCR/NAAT is encouraged for species confirmation and detection of mixed infections but should not replace immediate microscopy when acute clinical management is required.

When microscopy is unavailable, RDTs may be used for initial detection but must be followed by microscopy and, when indicated, NAAT for species confirmation.

Routine Zika testing is not recommended for asymptomatic pregnant patients living in or traveling to the United States and its territories given the lack of confirmed cases since 2018. When testing is indicated because of travel to areas with active CDC Zika Travel Health Notices or relevant exposures, NAAT may be considered up to 12 weeks after travel or symptom onset for pregnant individuals; for symptomatic non-pregnant recent travelers NAAT within 7 days of symptom onset is the preferred initial molecular test, with IgM and PRNT used per guidance for later time points or confirmatory testing.

For infants with congenital concerns or maternal exposure, perform NAAT and IgM testing on appropriate infant specimens and use PRNT for confirmatory serology when indicated.

Dengue serologic assays, especially IgG‑based EIA and hemagglutination tests, have limited specificity for diagnosing acute infection because IgG can reflect prior flavivirus exposures or vaccination. The CDC and guideline sources recommend against using IgG alone for acute dengue diagnosis and instead recommend acute-phase NAAT/NS1 antigen plus IgM testing (0–7 days) and IgM ELISA as the primary test after day 7; PRNT is advised when cross-reactivity confounds interpretation.

Clinicians should avoid ordering IgG serology for acute dengue unless paired acute and convalescent sera demonstrating a fourfold rise are obtained to support a recent infection.

Zika testing for symptomatic non-travelers (non-pregnant individuals without travel to areas with Zika transmission) does NOT meet coverage criteria — molecular and serologic testing for Zika should be limited to those with compatible travel/exposure history, pregnancy-related scenarios, symptomatic travelers, or infants with suggestive findings.

When testing is performed for pregnant individuals or those with relevant exposures, follow the specified NAAT timing windows (up to 12 weeks for certain pregnancy-related indications) and use IgM and PRNT as recommended to clarify results affected by cross-reactivity.

Arthropod vectors—including mosquitoes, ticks, fleas, and mites—transmit a range of bacterial, protozoal, and viral pathogens that cause diseases such as Lyme disease, babesiosis, malaria, dengue, Zika, West Nile virus, rickettsioses, relapsing fevers, and others. Diagnostic strategies depend on the suspected agent and timing of illness and commonly include microscopy, NAAT, antigen detection, serology (IFA/ELISA), and, where necessary, confirmatory testing such as PRNT or specialized tissue PCR/IHC performed at reference laboratories.